Oragenics announces ONP-002 completes FDA-required Genotoxicity Study

Oragenics announced its lead candidate for treating concussion, ONP-002, successfully completed a study that indicates it does not cause DNA damage and genotoxicity in an animal model. ONP-002 is a new chemical entity designed to target the brain through delivery into the nasal cavity and onward to the brain. Prior to conducting a clinical trial, the U.S. Food and Drug Administration requires that pharmaceuticals be tested on cells and animals to ensure they do not cause damage affecting cell division.